Search

Your search keyword '"Polonsky, William"' showing total 813 results
Start Over Author "Polonsky, William"
813 results on '"Polonsky, William"'

155. Identifying solutions to psychological insulin resistance: An international study

Author

Polonsky, William H., primary, Fisher, Lawrence, additional, Hessler, Danielle, additional, Stuckey, Heather, additional, Snoek, Frank J., additional, Tang, Tricia, additional, Hermanns, Norbert, additional, Mundet, Xavier, additional, Silva, Maria, additional, Sturt, Jackie, additional, Okazaki, Kentaro, additional, Hadjiyianni, Irene, additional, Cao, Dachuang, additional, Ivanova, Jasmina, additional, Desai, Urvi, additional, and Perez-Nieves, Magaly, additional

Published
2019
Full Text
View/download PDF

157. The value of episodic, intensive blood glucose monitoring in non-insulin treated persons with type 2 diabetes: Design of the Structured Testing Program (STeP) Study, a cluster-randomised, clinical trial [NCT00674986]

Author

Jelsovsky Zhihong, Parkin Christopher, Hinnen Deborah, Schikman Charles, Fisher Lawrence, Polonsky William, Amstutz Linda, Schweitzer Matthias, and Wagner Robin

Subjects
Medicine (General), R5-920
Abstract

Abstract Background The value and utility of self-monitoring of blood glucose (SMBG) in non-insulin treated T2DM has yet to be clearly determined. Findings from studies in this population have been inconsistent, due mainly to design differences and limitations, including the prescribed frequency and timing of SMBG, role of the patient and physician in responding to SMBG results, inclusion criteria that may contribute to untoward floor effects, subject compliance, and cross-arm contamination. We have designed an SMBG intervention study that attempts to address these issues. Methods/design The Structured Testing Program (STeP) study is a 12-month, cluster-randomised, multi-centre clinical trial to evaluate whether poorly controlled (HbA1c ≥ 7.5%), non-insulin treated T2DM patients will benefit from a comprehensive, integrated physician/patient intervention using structured SMBG in US primary care practices. Thirty-four practices will be recruited and randomly assigned to an active control group (ACG) that receives enhanced usual care or to an enhanced usual care group plus structured SMBG (STG). A total of 504 patients will be enrolled; eligible patients at each site will be randomly selected using a defined protocol. Anticipated attrition of 20% will yield a sample size of at least 204 per arm, which will provide a 90% power to detect a difference of at least 0.5% in change from baseline in HbA1c values, assuming a common standard deviation of 1.5%. Differences in timing and degree of treatment intensification, cost effectiveness, and changes in patient self-management behaviours, mood, and quality of life (QOL) over time will also be assessed. Analysis of change in HbA1c and other dependent variables over time will be performed using both intent-to-treat and per protocol analyses. Trial results will be available in 2010. Discussion The intervention and trial design builds upon previous research by emphasizing appropriate and collaborative use of SMBG by both patients and physicians. Utilization of per protocol and intent-to-treat analyses facilitates a comprehensive assessment of the intervention. Use of practice site cluster-randomisation reduces the potential for intervention contamination, and inclusion criteria (HbA1c ≥ 7.5%) reduces the possibility of floor effects. Inclusion of multiple dependent variables allows us to assess the broader impact of the intervention, including changes in patient and physician attitudes and behaviours. Trial Registration Current Controlled Trials NCT00674986.

Published
2010
Full Text
View/download PDF

160. Assessment of Diabetes-Related Distress

Author

Polonsky, William H., Anderson, Barbara J., Lohrer, Patricia A., Welch, Garry, Jacobson, Alan M., Aponte, Jennifer E., and Schwartz, Carolyn E.

Published
1995

163. A Randomized Clinical Trial of the Effect of Continuous Glucose Monitoring on Nocturnal Hypoglycemia, Daytime Hypoglycemia, Glycemic Variability, and Hypoglycemia Confidence in Persons with Type 1 Diabetes Treated with Multiple Daily Insulin Injections (GOLD-3)

Author

Olafsdottir, Arndis F., Polonsky, William, Bolinder, Jan, Hirsch, Irl B., Dahlqvist, Sofia, Wedel, Hans, Nystrom, Thomas, Wijkman, Magnus, Schwarcz, Erik, Hellman, Jarl, Heise, Tim, Lind, Marcus, Olafsdottir, Arndis F., Polonsky, William, Bolinder, Jan, Hirsch, Irl B., Dahlqvist, Sofia, Wedel, Hans, Nystrom, Thomas, Wijkman, Magnus, Schwarcz, Erik, Hellman, Jarl, Heise, Tim, and Lind, Marcus

Abstract

Background: To evaluate the effects of continuous glucose monitoring (CGM) on nocturnal and daytime hypoglycemia in persons with type 1 diabetes treated with multiple daily insulin injections (MDI); we also evaluated factors related to differences in hypoglycemia confidence in this population. Methods: Evaluations were performed from the GOLD randomized trial, an open-label multicenter crossover randomized clinical trial (n=161) over 69 weeks comparing CGM to self-measurement of blood glucose (SMBG) in persons with type 1 diabetes treated with MDI. Masked CGM and the hypoglycemia confidence questionnaire were used for evaluations. Results: Time with nocturnal hypoglycemia, glucose levels <70mg/dL was reduced by 48% (10.2 vs. 19.6min each night, P<0.001) and glucose levels <54mg/dL by 65%. (3.1 vs. 8.9min, P<0.001). For the corresponding glucose cutoffs, daytime hypoglycemia was reduced by 40% (29 vs. 49min, P<0.001) and 54% (8 vs. 18min., P<0.001), respectively. Compared with SMBG, CGM use improved hypoglycemia-related confidence in social situations (P=0.016) and confidence in more broadly avoiding serious problems due to hypoglycemia (P=0.0020). Persons also reported greater confidence in detecting and responding to decreasing blood glucose levels (thereby avoiding hypoglycemia) during CGM use (P=0.0033) and indicated greater conviction that they could more freely live their lives despite the risk of hypoglycemia (P=0.022). Conclusion: CGM reduced time in both nocturnal and daytime hypoglycemia in persons with type 1 diabetes treated with MDI and improved hypoglycemia-related confidence, especially in social situations, thus contributing to greater well-being and quality of life. Trial registration: ClinicalTrials.gov, number NCT02092051.

Published
2018
Full Text
View/download PDF

164. Sustained Intensive Treatment and Long-term Effects on HbA1c Reduction (SILVER Study) by CGM in People With Type 1 Diabetes Treated With MDI.

Author

Lind, Marcus, Ólafsdóttir, Arndís F., Hirsch, Irl B., Bolinder, Jan, Dahlqvist, Sofia, Pivodic, Aldina, Hellman, Jarl, Wijkman, Magnus, Schwarcz, Erik, Albrektsson, Henrik, Heise, Tim, and Polonsky, William

Subjects
TYPE 1 diabetes, TREATMENT effectiveness, PATIENT satisfaction, BLOOD sugar monitoring, OVERTIME, INSULINOMA, BLOOD sugar, HYPOGLYCEMIC agents, INSULIN, RANDOMIZED controlled trials, QUESTIONNAIRES, CROSSOVER trials, STATISTICAL sampling, SILVER
Abstract

Objective: Continuous glucose monitoring (CGM) reduces HbA1c and time spent in hypoglycemia in people with type 1 diabetes (T1D) treated with multiple daily insulin injections (MDI) when evaluated over shorter time periods. It is unclear to what extent CGM improves and helps to maintain glucose control, treatment satisfaction, diabetes distress, hypoglycemic concerns, and overall well-being over longer periods of time.Research Design and Methods: The GOLD trial was a randomized crossover trial performed over 16 months of CGM treatment in people with T1D treated with MDI. People completing the trial (n = 141) were invited to participate in the current SILVER extension study in which 107 patients continued CGM treatment over 1 year along with the support of a diabetes nurse every 3 months.Results: The primary end point of the change in HbA1c over 1.0-1.5 years of CGM use compared with previous self-monitoring of blood glucose during GOLD showed a decrease in HbA1c of 0.35% (95% CI 0.19-0.50, P < 0.001). Time spent in hypoglycemia <3.0 mmol/L (54 mg/dL) and <4.0 mmol/L (72 mg/dL) decreased from 2.1% to 0.6% (P < 0.001) and from 5.4% to 2.9% (P < 0.001), respectively. Overall well-being (World Health Organization 5-item well-being index, P = 0.009), treatment satisfaction (Diabetes Treatment Satisfaction Questionnaire, P < 0.001), and hypoglycemic confidence (P < 0.001) increased, while hypoglycemic fear (Hypoglycemia Fear Survey-Worry, P = 0.016) decreased and diabetes distress tended to decrease (Problem Areas in Diabetes Scale, P = 0.06). From randomization and screening in GOLD, HbA1c was lowered by 0.45% (P < 0.001) and 0.68% (P < 0.001) after 2.3 and 2.5 years, respectively.Conclusions: The SILVER study supports beneficial long-term effects from CGM on HbA1c, hypoglycemia, treatment satisfaction, well-being, and hypoglycemic confidence in people with T1D managed with MDI. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

166. The Association Between HbA1c and Time in Hypoglycemia During CGM and Self-Monitoring of Blood Glucose in People With Type 1 Diabetes and Multiple Daily Insulin Injections: A Randomized Clinical Trial (GOLD-4).

Author

Seyed Ahmadi, Shilan, Westman, Klara, Pivodic, Aldina, Ólafsdóttir, Arndís F., Dahlqvist, Sofia, Hirsch, Irl B., Hellman, Jarl, Ekelund, Magnus, Heise, Tim, Polonsky, William, Wijkman, Magnus, Schwarcz, Erik, and Lind, Marcus

Subjects
BLOOD sugar monitoring, TYPE 1 diabetes, CLINICAL trials, HYPOGLYCEMIA, INSULIN, BLOOD sugar analysis, RESEARCH, TIME, RESEARCH methodology, BLOOD sugar, MEDICAL cooperation, EVALUATION research, DRUG administration, COMPARATIVE studies, RANDOMIZED controlled trials, CROSSOVER trials, SUBCUTANEOUS injections
Abstract

Objective: According to recent guidelines, individuals with type 1 diabetes should spend <4.0% of time per day with glucose levels <3.9 mmol/L (<70 mg/dL) and <1.0% per day with glucose levels <3.0 mmol/L (<54 mg/dL).Research Design and Methods: In the GOLD randomized crossover trial, 161 individuals with type 1 diabetes treated with multiple daily insulin injections (MDI) were randomized to continuous glucose monitoring (CGM) or conventional therapy with self-monitoring of blood glucose (SMBG) and evaluated over 16 months. We estimated the association between time spent in hypoglycemia and various mean glucose and HbA1c levels.Results: Time spent in hypoglycemia (<3.9 mmol/L and <3.0 mmol/L) increased significantly with lower mean HbA1c and mean glucose levels during both CGM and conventional therapy. During CGM, 24 (57.1%) individuals with HbA1c <7.5% (<58 mmol/mol) had <1.0% time spent in hypoglycemia <3.0 mmol/L and 23 (54.8%) had <4.0% time spent in hypoglycemia <3.9 mmol/L. During CGM, mean time spent in hypoglycemia for individuals with mean HbA1c 7.0% (52 mmol/mol) was estimated to be 5.4% for <3.9 mmol/L and 1.5% for <3.0 mmol/L. The corresponding values during SMBG were 9.2% and 3.5%, respectively. Individuals with mean glucose levels of 8 mmol/L spent 4.9% units more time with glucose levels <3.9 mmol/L and 2.8% units more time <3.0 mmol/L during SMBG compared with CGM.Conclusions: Reaching current targets for time in hypoglycemia while at the same time reaching HbA1c targets is challenging for patients with type 1 diabetes treated with MDI both with CGM and SMBG monitoring. However, CGM is associated with considerably less time in hypoglycemia than SMBG at a broad range of HbA1c levels and is crucial for patients with MDI treatment if they are to have a chance to approach hypoglycemia targets. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

167. Successful Health-Care Provider Strategies to Overcome Psychological Insulin Resistance in the US and Canada

Author

Tang, Tricia, primary, Hessler, Danielle, additional, Polonsky, William H., additional, Fisher, Lawrence, additional, Hadjiyianni, Irene, additional, Cao, Dachuang, additional, Reed, Beverly, additional, Kalirai, Samaneh, additional, Irani, Tanya, additional, Ivanova, Jasmina, additional, Desai, Urvi, additional, and Perez-Nieves, Magaly, additional

Published
2018
Full Text
View/download PDF

170. T1-REDEEM: A Randomized Controlled Trial to Reduce Diabetes Distress Among Adults With Type 1 Diabetes

Author

Fisher, Lawrence, primary, Hessler, Danielle, additional, Polonsky, William H., additional, Masharani, Umesh, additional, Guzman, Susan, additional, Bowyer, Vicky, additional, Strycker, Lisa, additional, Ahmann, Andrew, additional, Basina, Marina, additional, Blumer, Ian, additional, Chloe, Charles, additional, Kim, Sarah, additional, Peters, Anne L., additional, Shumway, Martha, additional, Weihs, Karen, additional, and Wu, Patricia, additional

Published
2018
Full Text
View/download PDF

172. Successful Health Care Provider Strategies to Overcome Psychological Insulin Resistance in U.S. and Canada

Author

TANG, TRICIA S., primary, HESSLER, DANIELLE M., additional, POLONSKY, WILLIAM, additional, FISHER, LAWRENCE, additional, HADJIYIANNI, IRENE, additional, CAO, DACHUANG, additional, REED, BEVERLY, additional, KALIRAI, SAMANEH, additional, IRANI, TANYA, additional, IVANOVA, JASMINA I., additional, DESAI, URVI, additional, and PEREZ-NIEVES, MAGALY, additional

Published
2018
Full Text
View/download PDF

178. A Randomized Clinical Trial of the Effect of Continuous Glucose Monitoring on Nocturnal Hypoglycemia, Daytime Hypoglycemia, Glycemic Variability, and Hypoglycemia Confidence in Persons with Type 1 Diabetes Treated with Multiple Daily Insulin Injections (GOLD-3)

Author

Ólafsdóttir, Arndís F., primary, Polonsky, William, additional, Bolinder, Jan, additional, Hirsch, Irl B., additional, Dahlqvist, Sofia, additional, Wedel, Hans, additional, Nyström, Thomas, additional, Wijkman, Magnus, additional, Schwarcz, Erik, additional, Hellman, Jarl, additional, Heise, Tim, additional, and Lind, Marcus, additional

Published
2018
Full Text
View/download PDF

180. Diabetes-Related Emotion Regulation Measure

Author

Fisher, Lawrence, primary, Hessler, Danielle, additional, Polonsky, William, additional, Strycker, Lisa, additional, Guzman, Susan, additional, Bowyer, Vicky, additional, Blumer, Ian, additional, and Masharani, Umesh, additional

Published
2018
Full Text
View/download PDF

183. INSIDER SECRETS.

Author

FILATOFF, NATALIE, Linjawi, Sultan, YOUNG, FIONA, GRENFELL, ROBERT, FELTON, JOHN, Joshy, Grace, Polonsky, William, Bais, Lauren, and Walker, Ross

Published
2021

184. Role of continuous glucose monitoring in clinical trials: Recommendations on reporting

Author

Schnell, Oliver, Barnard, Katharine, Bergenstal, Richard, Bosi, Emanuele, Garg, Satish, Guerci, Bruno, Haak, Thomas, Hirsch, Irl, Ji, Linong, Joshi, Shashank, Kamp, Maarten, Laffel, Lori, Mathieu, Chantal, Polonsky, William, Snoek, Frank, Home, Philip, Schnell, Oliver, Barnard, Katharine, Bergenstal, Richard, Bosi, Emanuele, Garg, Satish, Guerci, Bruno, Haak, Thomas, Hirsch, Irl, Ji, Linong, Joshi, Shashank, Kamp, Maarten, Laffel, Lori, Mathieu, Chantal, Polonsky, William, Snoek, Frank, and Home, Philip

Published
2017

186. Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors

Author

Polonsky, William and Henry,Robert

Subjects
Patient Preference and Adherence
Abstract

William H Polonsky,1,2 Robert R Henry2,3 1Behavioral Diabetes Institute, San Diego, 2University of California, San Diego, 3Center for Metabolic Research, VA San Diego Healthcare System, SanDiego, CA, USA Abstract: At least 45% of patients with type 2 diabetes (T2D) fail to achieve adequate glycemic control (HbA1c

Published
2016

188. Self-monitoring of blood glucose in noninsulin-using type 2 diabetic patients: right answer, but wrong question: self-monitoring of blood glucose can be clinically valuable for noninsulin users.

Author

Polonsky, William, Polonsky, William, Fisher, Lawrence, Polonsky, William, Polonsky, William, and Fisher, Lawrence

Abstract

Given the importance of glycemic control in the development of diabetes complications, the plethora of tools now available to monitor the day-to-day trends in glycemia is remarkable. In this regard, self-monitoring of blood glucose (SMBG) has been considered a key component of patient management. Arguably, there remains almost universal agreement that SMBG should be available to all diabetic patients regardless of current treatment strategy. However, recently there have been reports that have challenged the current paradigm that all patients should use SMBG and concluded that SMBG for type 2 diabetic patients not on insulin may not be beneficial on glycemic control and must be weighed against the expense and inconvenience. In the counterpoint narrative following the contribution by Malanda et al., Drs. Polonsky and Fisher provide a compelling argument suggesting that while it is evident that implementing SMBG in unstructured ways without training patients and clinicians is likely to be a waste of resources, there are effective and powerful ways to use structured SMBG in insulin-naïve type 2 diabetic patients. -William T. Cefalu, MD Editor in Chief, Diabetes Care.

Published
2013

189. Consensus Report of the Coalition for Clinical Research—Self-Monitoring of Blood Glucose

Author

Klonoff, David C., Bergenstal, Richard, Blonde, Lawrence, Boren, Suzanne Austin, Church, Timothy S., Gaffaney, Jenifer, Jovanovič, Lois, Kendall, David M., Kollman, Craig, Kovatchev, Boris P., Leippert, Claudia, DDG, Diabetesberaterin, Owens, David R., Polonsky, William H., Reach, Gérard, Renard, Eric, Riddell, Michael C., Rubin, Richard R., Schnell, Oliver, Siminiero, Linda M., Vigersky, Robert A., Wilson, Darrell M., and Wollitzer, Alison Okada

Subjects
medicine.medical_specialty, endocrine system diseases, business.industry, Endocrinology, Diabetes and Metabolism, Biomedical Engineering, Psychological intervention, nutritional and metabolic diseases, Bioengineering, Original Articles, Bioinformatics, law.invention, Clinical trial, Clinical research, Quality of life (healthcare), Randomized controlled trial, law, Family medicine, Internal Medicine, medicine, Health education, Cluster randomised controlled trial, business, Medical literature
Abstract

The Coalition for Clinical Research—Self-Monitoring of Blood Glucose Scientific Board, a group of nine academic clinicians and scientists from the United States and Europe, convened in San Francisco, California, on June 11–12, 2008, to discuss the appropriate uses of self-monitoring of blood glucose (SMBG) and the measures necessary to accurately assess the potential benefit of this practice in noninsulin-treated type 2 diabetes mellitus (T2DM). Thirteen consultants from the United States, Europe, and Canada from academia, practice, and government also participated and contributed based on their fields of expertise. These experts represent a range of disciplines that include adult endocrinology, pediatric endocrinology, health education, mathematics, statistics, psychology, nutrition, exercise physiology, and nursing. This coalition was organized by Diabetes Technology Management, Inc. Among the participants, there was consensus that: 1. protocols assessing the performance of SMBG in noninsulin treated T2DM must provide the SMBG intervention subjects with blood glucose (BG) goals and instructions on how to respond to BG data in randomized controlled trials (RCTs); 2. intervention subjects in clinical trials of SMBG-driven interventions must aggressively titrate their therapeutic responses or lifestyle changes in response to hyperglycemia; 3. control subjects in clinical trials of SMBG must be isolated from SMBG-driven interventions and not be contaminated by physician experience with study subjects receiving a SMBG intervention; 4. the best endpoints to measure in a clinical trial of SMBG in T2DM include delta Hemoglobin A1c levels, hyperglycemic events, hypoglycemic events, time to titrate noninsulin therapy to a maximum necessary dosage, and quality of life indices; 5. either individual randomization or cluster randomization may be appropriate methods for separating control subjects from SMBG intervention subjects, provided that precautions are taken to avoid bias and that the sample size is adequate; 6. treatment algorithms for assessing SMBG in T2DM may include a dietary, exercise, and/or medication intervention, which are all titratable according to the SMBG values; 7. the medical literature contains very little information about the performance of SMBG in T2DM from RCTs in which treatment algorithms were used for dysglycemic values; and 8. research on the performance of SMBG in T2DM based on sound scientific principles and clinical practices is needed at this time.

Published
2008
Full Text
View/download PDF

190. Effect of initiating use of an insulin pump in adults with type 1 diabetes using multiple daily insulin injections and continuous glucose monitoring (DIAMOND): a multicentre, randomised controlled trial

Author

Beck, Roy W, primary, Riddlesworth, Tonya D, additional, Ruedy, Katrina J, additional, Kollman, Craig, additional, Ahmann, Andrew J, additional, Bergenstal, Richard M, additional, Bhargava, Anuj, additional, Bode, Bruce W, additional, Haller, Stacie, additional, Kruger, Davida F, additional, McGill, Janet B, additional, Polonsky, William, additional, Price, David, additional, Toschi, Elena, additional, Wolpert, Howard, additional, Atakov-Castillo, Astrid, additional, Markovic, Edvina, additional, Aronoff, Stephen, additional, Brooks, Satanya, additional, Martinez, Gloria, additional, Mendez, Angela, additional, Dunnam, Theresa, additional, Fitzgerald, Kathy, additional, Wright, Diana, additional, Khoo, Teck, additional, Theuma, Pierre, additional, Herrold, Tara, additional, Thomsen, Debra, additional, Bergenstal, Richard, additional, McCann, Kathleen, additional, Monk, Arlene, additional, Ashanti, Char, additional, Liljenquist, David, additional, Judge, Heather, additional, Halford, Jean, additional, Kruger, Davida, additional, Levy, Shiri, additional, Bhan, Arti, additional, Cushman, Terra, additional, Dawson, Lameka, additional, Remtema, Heather, additional, Wolf, Fawn, additional, Neifing, James, additional, Murdoch, Jennifer, additional, Staat, Susan, additional, Mayfield, Tamara, additional, Ahmann, Andrew, additional, Klopfenstein, Bethany, additional, Joarder, Farahnaz, additional, Hanavan, Kathy, additional, Castle, Jessica, additional, Aby-Daniel, Diana, additional, Morimoto, Victoria, additional, DeFrang, Donald, additional, Wollam, Bethany, additional, McGill, Janet, additional, Jordan, Olivia, additional, Recklein, Carol, additional, Kipnes, Mark, additional, Ryan, Terri, additional, Bode, Bruce, additional, Boyd, Jennifer, additional, Rastogi, Nitin, additional, Lindmark, Katherine, additional, Biggs, William, additional, Sandoval, Lorena, additional, Eifert, Robin, additional, Cota, Becky, additional, Nguyen, Quang, additional, Martinez, Alejandra, additional, Duran, Cathy, additional, Segel, Scott, additional, Sutton, David, additional, Roura, Miguel, additional, Rosenwasser, Rebecca, additional, McElveen, Jennifer, additional, Knisely, Emily, additional, Johnson, Anne, additional, Odugbesan, A. Ola, additional, Wardell, Karla, additional, Paulus, Carolyn, additional, Wahlen, Jack, additional, Winkfield, Jon, additional, Wahlen, Hilary, additional, Hepworth, Emily, additional, Winkfield, David, additional, Owens, Sue, additional, Leichter, Steven, additional, Evans, Emily, additional, Konigsberg, Sarah, additional, Rahman, Jennifer, additional, Gaudiani, Linda, additional, Woods, Natalie, additional, Cardozo, Jesse, additional, Wheeler, Kate, additional, Kane, Jennifer, additional, Eubanks, Terri, additional, Ruedy, Katrina, additional, Beck, Roy W., additional, Riddlesworth, Tonya, additional, Mouse, Thomas, additional, Casal, Eileen, additional, and Graham, Claudia, additional

Published
2017
Full Text
View/download PDF

193. Initiating insulin: How to help people with type 2 diabetes start and continue insulin successfully

Author

Polonsky, William H., primary, Arsenault, Joyce, additional, Fisher, Lawrence, additional, Kushner, Pamela, additional, Miller, Eden M., additional, Pearson, Teresa L., additional, Tracz, Mariusz, additional, Harris, Stewart, additional, Hermanns, Norbert, additional, Scholz, Bernd-M., additional, Pollom, Robyn K., additional, Perez-Nieves, Magaly, additional, Pollom, Roy Daniel, additional, and Hadjiyianni, Irene, additional

Published
2017
Full Text
View/download PDF

194. Role of Continuous Glucose Monitoring in Clinical Trials: Recommendations on Reporting

Author

Schnell, Oliver, primary, Barnard, Katharine, additional, Bergenstal, Richard, additional, Bosi, Emanuele, additional, Garg, Satish, additional, Guerci, Bruno, additional, Haak, Thomas, additional, Hirsch, Irl B., additional, Ji, Linong, additional, Joshi, Shashank R., additional, Kamp, Maarten, additional, Laffel, Lori, additional, Mathieu, Chantal, additional, Polonsky, William H., additional, Snoek, Frank, additional, and Home, Philip, additional

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results